Novel Concepts in HDL Pharmacology

Overview

Journal Cardiovasc Res

Specialty Cardiology & Vascular Diseases

Date 2014 Jun 22

PMID 24951539

Citations 14

Authors

Alan T Remaley

Giuseppe D Norata

Alberico L Catapano

Affiliations

Soon will be listed here.

Abstract

High-density lipoproteins (HDL) are a target for drug development because of their proposed anti-atherogenic properties. In this review, we will briefly discuss the currently established drugs for increasing HDL-C, namely niacin and fibrates, and some of their limitations. Next, we will focus on novel alternative therapies that are currently being developed for raising HDL-C, such as CETP inhibitors. Finally, we will conclude with a review of novel drugs that are being developed for modulating the function of HDL based on HDL mimetics. Gaps in our knowledge and the challenges that will have to be overcome for these new HDL based therapies will also be discussed.

Citing Articles

Designer high-density lipoprotein particles enhance endothelial barrier function and suppress inflammation.

Lin Y, Swendeman S, Moreira I, Ghosh A, Kuo A, Rosario-Ferreira N Sci Signal. 2024; 17(824):eadg9256.

PMID: 38377179 PMC: 10954247. DOI: 10.1126/scisignal.adg9256.

A decreased level of high-density lipoprotein is a possible risk factor for type 2 diabetes mellitus: A review.

Bodaghi A, Ebadi E, Gholami M, Azizi R, Shariati A Health Sci Rep. 2023; 6(12):e1779.

PMID: 38125279 PMC: 10731824. DOI: 10.1002/hsr2.1779.

Alterations of HDL's to piHDL's Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies.

Vyletelova V, Novakova M, Paskova L Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297390 PMC: 9611871. DOI: 10.3390/ph15101278.

Dietary Palmitoleic Acid Attenuates Atherosclerosis Progression and Hyperlipidemia in Low-Density Lipoprotein Receptor-Deficient Mice.

Yang Z, Pryor M, Noguchi A, Sampson M, Johnson B, Pryor M Mol Nutr Food Res. 2019; 63(12):e1900120.

PMID: 30921498 PMC: 6584074. DOI: 10.1002/mnfr.201900120.

Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension.

Harbaum L, Ghataorhe P, Wharton J, Jimenez B, Howard L, Gibbs J Thorax. 2018; 74(4):380-389.

PMID: 30478197 PMC: 6475111. DOI: 10.1136/thoraxjnl-2018-212144.

References

Brunham L, Tietjen I, Bochem A, Singaraja R, Franchini P, Radomski C . Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans. Clin Genet. 2011; 79(6):575-81. DOI: 10.1111/j.1399-0004.2011.01682.x. View

Remaley A, Stonik J, Demosky S, Neufeld E, Bocharov A, Vishnyakova T . Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun. 2001; 280(3):818-23. DOI: 10.1006/bbrc.2000.4219. View

Lamon-Fava S, Diffenderfer M, Barrett P, Buchsbaum A, Nyaku M, Horvath K . Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2008; 28(9):1672-8. PMC: 2761712. DOI: 10.1161/ATVBAHA.108.164541. View

Tardif J, Gregoire J, LAllier P, Ibrahim R, LEsperance J, Heinonen T . Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007; 297(15):1675-82. DOI: 10.1001/jama.297.15.jpc70004. View

Norata G, Pirillo A, Ammirati E, Catapano A . Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 2011; 220(1):11-21. DOI: 10.1016/j.atherosclerosis.2011.06.045. View

Voisset C, Callens N, Blanchard E, Op de Beeck A, Dubuisson J, Vu-Dac N . High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem. 2005; 280(9):7793-9. DOI: 10.1074/jbc.M411600200. View

Rousset X, Vaisman B, Auerbach B, Krause B, Homan R, Stonik J . Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Ther. 2010; 335(1):140-8. PMC: 2957790. DOI: 10.1124/jpet.110.169540. View

Norata G, Sala F, Catapano A, Fernandez-Hernando C . MicroRNAs and lipoproteins: a connection beyond atherosclerosis?. Atherosclerosis. 2012; 227(2):209-15. PMC: 4193445. DOI: 10.1016/j.atherosclerosis.2012.11.019. View

Rader D . Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med. 2007; 4(2):102-9. DOI: 10.1038/ncpcardio0768. View

10.

Diditchenko S, Gille A, Pragst I, Stadler D, Waelchli M, Hamilton R . Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol. 2013; 33(9):2202-11. DOI: 10.1161/ATVBAHA.113.301981. View

11.

Krause B, Remaley A . Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol. 2013; 24(6):480-6. DOI: 10.1097/MOL.0000000000000020. View

12.

Mineo C, Shaul P . Functions of scavenger receptor class B, type I in atherosclerosis. Curr Opin Lipidol. 2012; 23(5):487-93. DOI: 10.1097/MOL.0b013e328357ba61. View

13.

Norata G, Ballantyne C, Catapano A . New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J. 2013; 34(24):1783-9. PMC: 3857929. DOI: 10.1093/eurheartj/eht088. View

14.

Barter P . HDL-C: role as a risk modifier. Atheroscler Suppl. 2011; 12(3):267-70. DOI: 10.1016/S1567-5688(11)70885-6. View

15.

Rader D . Illuminating HDL--is it still a viable therapeutic target?. N Engl J Med. 2007; 357(21):2180-3. DOI: 10.1056/NEJMe0707210. View

16.

Rosenson R, Brewer Jr H, Chapman M, Fazio S, Hussain M, Kontush A . HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011; 57(3):392-410. DOI: 10.1373/clinchem.2010.155333. View

17.

Norata G, Pirillo A, Catapano A . HDLs, immunity, and atherosclerosis. Curr Opin Lipidol. 2011; 22(5):410-6. DOI: 10.1097/MOL.0b013e32834adac3. View

18.

Luscher T, Taddei S, Kaski J, Jukema J, Kallend D, Munzel T . Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012; 33(7):857-65. PMC: 3345558. DOI: 10.1093/eurheartj/ehs019. View

19.

Nicholls S, Gordon A, Johansson J, Wolski K, Ballantyne C, Kastelein J . Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011; 57(9):1111-9. DOI: 10.1016/j.jacc.2010.11.015. View

20.

Barter P, Caulfield M, Eriksson M, Grundy S, Kastelein J, Komajda M . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-22. DOI: 10.1056/NEJMoa0706628. View